{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T22:57:26Z","timestamp":1770677846591,"version":"3.49.0"},"reference-count":111,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01CA217923"],"award-info":[{"award-number":["R01CA217923"]}]},{"name":"NIH","award":["R21ES034811"],"award-info":[{"award-number":["R21ES034811"]}]},{"name":"NIH","award":["T32 ES007324"],"award-info":[{"award-number":["T32 ES007324"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bladder cancer, the most common malignancy of the urinary tract, has a poor overall survival rate when the tumor becomes muscle invasive. The discovery and evaluation of new alternative medications targeting high-grade muscle invasive bladder cancer (MIBC) are of tremendous importance in reducing bladder cancer mortality. Isorhapontigenin (ISO), a stilbene derivative from the Chinese herb Gnetum cleistostachyum, exhibits a strong anti-cancer effect on MIBCs. Here, we report the whole transcriptome profiling of ISO-treated human bladder cancer T24 cells. A total of 1047 differentially expressed genes (DEGs) were identified, including 596 downregulated and 451 upregulated genes. Functional annotation and pathway analysis revealed that ISO treatment induced massive changes in gene expression associated with cell movement, migration, invasion, metabolism, proliferation, and angiogenesis. Additionally, ISO treatment-activated genes involved in the inflammatory response but repressed genes involved in hypoxia signaling, glycolysis, the actin cytoskeleton, and the tumor microenvironment. In summary, our whole transcriptome analysis demonstrated a shift in metabolism and altered actin cytoskeleton in ISO-treated T24 cells, which subsequently contribute to tumor microenvironment remodeling that suppresses tumor growth and progression.<\/jats:p>","DOI":"10.3390\/ijms25031783","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T08:44:08Z","timestamp":1706777048000},"page":"1783","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder Cancer Cells"],"prefix":"10.3390","volume":"25","author":[{"given":"Alex H.","family":"Li","sequence":"first","affiliation":[{"name":"Division of Environmental Medicine, Department of Medicine, NYU Grossman School of Medicine, 341 East 25th Street, New York, NY 10010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine, Department of Medicine, NYU Grossman School of Medicine, 341 East 25th Street, New York, NY 10010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiwei","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine, Department of Medicine, NYU Grossman School of Medicine, 341 East 25th Street, New York, NY 10010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoting","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine, Department of Medicine, NYU Grossman School of Medicine, 341 East 25th Street, New York, NY 10010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kluz","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine, Department of Medicine, NYU Grossman School of Medicine, 341 East 25th Street, New York, NY 10010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxia","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine, Department of Medicine, NYU Grossman School of Medicine, 341 East 25th Street, New York, NY 10010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Costa","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine, Department of Medicine, NYU Grossman School of Medicine, 341 East 25th Street, New York, NY 10010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9885-4797","authenticated-orcid":false,"given":"Hong","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Environmental Medicine, Department of Medicine, NYU Grossman School of Medicine, 341 East 25th Street, New York, NY 10010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref_1","first-page":"e27330","article-title":"A Review of the Etiology and Epidemiology of Bladder Cancer: All You Need To Know","volume":"14","author":"Halaseh","year":"2022","journal-title":"Cureus"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., Padala, S.A., and Barsouk, A. (2020). Epidemiology of Bladder Cancer. Med. Sci., 8.","DOI":"10.3390\/medsci8010015"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e223050","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004\u20132013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35234","DOI":"10.1074\/jbc.M112.389494","article-title":"The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP","volume":"287","author":"Fang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pecyna, P., Wargula, J., Murias, M., and Kucinska, M. (2020). More Than Resveratrol: New Insights into Stilbene-Based Compounds. Biomolecules, 10.","DOI":"10.3390\/biom10081111"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1007\/s10753-019-01092-0","article-title":"Isorhapontigenin Suppresses Interleukin-1\u03b2-Induced Inflammation and Cartilage Matrix Damage in Rat Chondrocytes","volume":"42","author":"Ma","year":"2019","journal-title":"Inflammation"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Li, W., Hu, S., Chen, X., and Shi, J. (2021). The Antioxidant Resveratrol Protects against Chondrocyte Apoptosis by Regulating the COX-2\/NF-\u03baB Pathway in Created Temporomandibular Osteoarthritis. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/9978651"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2011.10.015","article-title":"Resveratrol inhibits interleukin 1\u03b2-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-\u03baB activity","volume":"674","author":"Lei","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3328623","DOI":"10.1155\/2022\/3328623","article-title":"Isorhapontigenin Modulates SOX9\/TOLLIP Expression to Attenuate Cell Apoptosis and Oxidative Stress in Paraquat-Induced Acute Kidney Injury","volume":"2022","author":"Zheng","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3389\/fphar.2018.00753","article-title":"Pre-clinical Pharmacokinetic and Metabolomic Analyses of Isorhapontigenin, a Dietary Resveratrol Derivative","volume":"9","author":"Dai","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Subedi, L., Teli, M.K., Lee, J.H., Gaire, B.P., Kim, M.H., and Kim, S.Y. (2019). A Stilbenoid Isorhapontigenin as a Potential Anti-Cancer Agent against Breast Cancer through Inhibiting Sphingosine Kinases\/Tubulin Stabilization. Cancers, 11.","DOI":"10.3390\/cancers11121947"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1111\/bph.13803","article-title":"Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism","volume":"174","author":"Yeo","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.omtn.2018.05.017","article-title":"ISO, via Upregulating MiR-137 Transcription, Inhibits GSK3\u03b2-HSP70-MMP-2 Axis, Resulting in Attenuating Urothelial Cancer Invasion","volume":"12","author":"Guo","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/15548627.2016.1179403","article-title":"SESN2\/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers","volume":"12","author":"Liang","year":"2016","journal-title":"Autophagy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.canlet.2021.07.041","article-title":"Isorhapontigenin (ISO) inhibits EMT through FOXO3A\/METTL14\/VIMENTIN pathway in bladder cancer cells","volume":"520","author":"Zhang","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1940-6207.CAPR-15-0338","article-title":"Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1\/FOXO1 Axis","volume":"9","author":"Jiang","year":"2016","journal-title":"Cancer Prev. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00018-019-03185-3","article-title":"Isorhapontigenin (ISO) inhibits stem cell-like properties and invasion of bladder cancer cell by attenuating CD44 expression","volume":"77","author":"Luo","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41419-022-05205-w","article-title":"Induction of RAC1 protein translation and MKK7\/JNK-dependent autophagy through dicer\/miR-145\/SOX2\/miR-365a axis contributes to isorhapontigenin (ISO) inhibition of human bladder cancer invasion","volume":"13","author":"Hua","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1158\/1535-7163.MCT-12-0922","article-title":"Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells","volume":"12","author":"Fang","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/neuonc\/nov298","article-title":"Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145\/SOX2\/cyclin D1 axis","volume":"18","author":"Xu","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","article-title":"The role of carbonic anhydrase IX in cancer development: Links to hypoxia, acidosis, and beyond","volume":"38","author":"Pastorekova","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.7150\/ijbs.65174","article-title":"Integrin-\u03b24 regulates the dynamic changes of phenotypic characteristics in association with epithelial-mesenchymal transition (EMT) and RhoA activity in airway epithelial cells during injury and repair","volume":"18","author":"Tan","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.2147\/IJGM.S341076","article-title":"A Pan-Cancer Analysis of the Oncogenic Role of Integrin Beta4 (ITGB4) in Human Tumors","volume":"14","author":"Huang","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1007\/s11033-023-08540-z","article-title":"A review on the role of NDRG1 in different cancers","volume":"50","author":"Hussen","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3892\/ol.2011.394","article-title":"Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder","volume":"2","author":"Reis","year":"2011","journal-title":"Oncol. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","article-title":"Metabolic phenotype of bladder cancer","volume":"45","author":"Massari","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2004-07-2958","article-title":"Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1","volume":"105","author":"Manalo","year":"2005","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1007\/s11033-023-08512-3","article-title":"MDM2- an indispensable player in tumorigenesis","volume":"50","author":"Zafar","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/ejhg.2016.93","article-title":"The biological effects and clinical implications of BRCA mutations: Where do we go from here?","volume":"24","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.18632\/oncotarget.1872","article-title":"Isorhapontigenin (ISO) inhibited cell transformation by inducing G0\/G1 phase arrest via increasing MKP-1 mRNA Stability","volume":"5","author":"Gao","year":"2014","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Huang, M., Hua, X., Xu, J., Tian, Z., Wang, J., Chen, H., Wang, X., Shu, P., Ye, H., and Shu, J. (2022). Induction of p27 contributes to inhibitory effect of isorhapontigenin (ISO) on malignant transformation of human urothelial cells. Cell Cycle, 1\u201314.","DOI":"10.1080\/15384101.2022.2074623"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/carcin\/bgy015","article-title":"Transcriptional and post-transcriptional upregulation of p27 mediates growth inhibition of isorhapontigenin (ISO) on human bladder cancer cells","volume":"39","author":"Jiang","year":"2018","journal-title":"Carcinogenesis"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Izdebska, M., Zieli\u0144ska, W., Grzanka, D., and Gagat, M. (2018). The Role of Actin Dynamics and Actin-Binding Proteins Expression in Epithelial-to-Mesenchymal Transition and Its Association with Cancer Progression and Evaluation of Possible Therapeutic Targets. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/4578373"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101051","DOI":"10.1016\/j.tranon.2021.101051","article-title":"The remodelling of actin composition as a hallmark of cancer","volume":"14","author":"Suresh","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Aseervatham, J. (2020). Cytoskeletal Remodeling in Cancer. Biology, 9.","DOI":"10.3390\/biology9110385"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.ircmb.2021.02.017","article-title":"Cancer type-specific alterations in actin genes: Worth a closer look?","volume":"360","author":"Ampe","year":"2021","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1089\/dna.2021.0416","article-title":"Silencing ACTG1 Expression Induces Prostate Cancer Epithelial Mesenchymal Transition Through MAPK\/ERK Signaling Pathway","volume":"40","author":"Xiao","year":"2021","journal-title":"DNA Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14556","DOI":"10.18632\/oncotarget.3989","article-title":"Tumor promotion by \u03b3 and suppression by \u03b2 non-muscle actin isoforms","volume":"6","author":"Dugina","year":"2015","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-18-4080","article-title":"Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival","volume":"79","author":"Chang","year":"2019","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e2739","DOI":"10.1038\/cddis.2017.61","article-title":"miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis","volume":"8","author":"Liu","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Schwartz, M.A. (2010). Integrins and extracellular matrix in mechanotransduction. Cold Spring Harb. Perspect. Biol., 2.","DOI":"10.1101\/cshperspect.a005066"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1242\/jcs.018564","article-title":"Integrins in cell migration\u2014The actin connection","volume":"122","author":"Choi","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.7150\/jca.29269","article-title":"ITGB4 is a novel prognostic factor in colon cancer","volume":"10","author":"Li","year":"2019","journal-title":"J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/labinvest.2014.166","article-title":"Upregulation of integrin \u03b24 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma","volume":"95","author":"Masugi","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_51","first-page":"8611306","article-title":"ITGA5 Promotes Tumor Progression through the Activation of the FAK\/AKT Signaling Pathway in Human Gastric Cancer","volume":"2022","author":"Wang","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhu, H., Wang, G., Zhu, H., and Xu, A. (2021). ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07996-1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.279.5350.509","article-title":"Rho GTPases and the actin cytoskeleton","volume":"279","author":"Hall","year":"1998","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","article-title":"Metabolic adaptation in hypoxia and cancer","volume":"502","author":"Paredes","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","article-title":"Hypoxia-inducible factors: Master regulators of hypoxic tumor immune escape","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zimna, A., and Kurpisz, M. (2015). Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/549412"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"849040","DOI":"10.3389\/fgene.2022.849040","article-title":"Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism","volume":"13","author":"Sharma","year":"2022","journal-title":"Front. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1111\/febs.14577","article-title":"Glucose transporters in cancer\u2014From tumor cells to the tumor microenvironment","volume":"285","author":"Ancey","year":"2018","journal-title":"FEBS J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"43407","DOI":"10.1074\/jbc.M108181200","article-title":"Glucose catabolism in cancer cells: Identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions","volume":"276","author":"Mathupala","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","article-title":"Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer","volume":"24","author":"Patra","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2022.11.007","article-title":"Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics","volume":"87","author":"Sharma","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cpt.2022.09.001","article-title":"PI3K\/AKT\/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung cancer","volume":"1","author":"Deng","year":"2023","journal-title":"Cancer Pathog. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: Targets, trials and biomarkers","volume":"6","author":"Paplomata","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1074\/jbc.M512502200","article-title":"Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B","volume":"281","author":"Voigt","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"20312","DOI":"10.1073\/pnas.0905506106","article-title":"Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87\/p110gamma","volume":"106","author":"Kurig","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/cam4.2810","article-title":"RAPTOR promotes colorectal cancer proliferation by inducing mTORC1 and upregulating ribosome assembly factor URB1","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Earwaker, P., Anderson, C., Willenbrock, F., Harris, A.L., Protheroe, A.S., and Macaulay, V.M. (2018). RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191890"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/carcin\/bgp258","article-title":"Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk","volume":"30","author":"Chen","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/ncb1753","article-title":"Regulation of TORC1 by Rag GTPases in nutrient response","volume":"10","author":"Kim","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100307","DOI":"10.1016\/j.aohep.2021.100307","article-title":"Ras related GTP binding D promotes aerobic glycolysis of hepatocellular carcinoma","volume":"23","author":"Ding","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.aag2553","article-title":"Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth","volume":"356","author":"Siciliano","year":"2017","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.celrep.2015.07.016","article-title":"A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation","volume":"12","author":"Yang","year":"2015","journal-title":"Cell Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","article-title":"Akt, FoxO and regulation of apoptosis","volume":"1813","author":"Zhang","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.onc.1210715","article-title":"Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1","volume":"27","author":"Averous","year":"2008","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/1535-7163.MCT-15-0606","article-title":"Induction of miR-137 by Isorhapontigenin (ISO) Directly Targets Sp1 Protein Translation and Mediates Its Anticancer Activity both In Vitro and In Vivo","volume":"15","author":"Zeng","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"606874","DOI":"10.3389\/fimmu.2020.606874","article-title":"Context Is Key: Delineating the Unique Functions of IFN\u03b1 and IFN\u03b2 in Disease","volume":"11","author":"Fox","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-alpha\/beta signalling to p53 responses in tumour suppression and antiviral defence","volume":"424","author":"Takaoka","year":"2003","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e12863","DOI":"10.1111\/sji.12863","article-title":"Interferon \u03b1 in cancer immunoediting: From elimination to escape","volume":"91","author":"Vidal","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Jorgovanovic, D., Song, M., Wang, L., and Zhang, Y. (2020). Roles of IFN-\u03b3 in tumor progression and regression: A review. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00228-x"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Baker, S.C., Mason, A.S., Slip, R.G., Eriksson, P., Sj\u00f6dahl, G., Trejdosiewicz, L.K., and Southgate, J. (2022). The Urothelial Transcriptomic Response to Interferon Gamma: Implications for Bladder Cancer Prognosis and Immunotherapy. Cancers, 14.","DOI":"10.3390\/cancers14215295"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e121062","DOI":"10.1172\/jci.insight.121062","article-title":"CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade","volume":"3","author":"Sato","year":"2018","journal-title":"JCI Insight"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"Joyce","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: Accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Dominiak, A., Che\u0142stowska, B., Olejarz, W., and Nowicka, G. (2020). Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions. Cancers, 12.","DOI":"10.3390\/cancers12051232"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/156800909789057006","article-title":"The role of fibroblast growth factors in tumor growth","volume":"9","author":"Korc","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/joim.12019","article-title":"VEGFA and tumour angiogenesis","volume":"273","author":"Welsh","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/14728222.2014.948420","article-title":"Placental growth factor in cancer","volume":"18","author":"Dewerchin","year":"2014","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijbiomac.2022.01.113","article-title":"Targeting the PDGF\/PDGFR signaling pathway for cancer therapy: A review","volume":"202","author":"Zou","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cytogfr.2005.04.007","article-title":"CXC chemokines in angiogenesis","volume":"16","author":"Strieter","year":"2005","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ijc.2910110327","article-title":"Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen","volume":"11","author":"Donner","year":"1973","journal-title":"Int. J. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:53:11Z","timestamp":1760104391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":111,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25031783"],"URL":"https:\/\/doi.org\/10.3390\/ijms25031783","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}